
Thermo Fisher Scientific PPP2R5D Monoclonal Antibody (OTI10D11), TrueMAB
PPP2R5D 단백질을 인식하는 마우스 단클론 항체로 Western blot에 적합. 정제된 액상 형태이며 1 mg/mL 농도. PBS, BSA, 글리세롤 버퍼에 보존되고 -20°C에서 보관. 연구용으로만 사용 가능.
- 카탈로그번호
- TA804123
- 판매단위
- pk
카탈로그
1개 옵션 · 카탈로그 번호를 클릭하면 복사됩니다Thermo Fisher Scientific · Thermo Fisher Scientific PPP2R5D Monoclonal Antibody (OTI10D11), TrueMAB
Applications
- Western Blot (WB): 1:2,000 dilution tested
Product Specifications
| 항목 | 내용 |
|---|---|
| Species Reactivity | Human |
| Host / Isotype | Mouse / IgG1 |
| Class | Monoclonal |
| Type | Antibody |
| Clone | OTI10D11 |
| Immunogen | Full length human recombinant protein of human PPP2R5D produced in E. coli |
| Conjugate | Unconjugated |
| Form | Liquid |
| Concentration | 1 mg/mL |
| Purification | Affinity chromatography |
| Storage Buffer | PBS with 1% BSA, 50% glycerol |
| Contains | 0.02% sodium azide |
| Storage Conditions | -20°C, Avoid Freeze/Thaw Cycles |
| Shipping Conditions | Ambient (domestic); Wet ice (international) |
Target Information
Zinc-finger proteins contain DNA-binding domains and have a wide variety of functions, most of which encompass some form of transcriptional activation or repression.
ZNF265 (Zinc finger protein 265), also known as ZRANB2 (Zinc finger Ran-binding domain-containing protein 2), ZIS, ZIS1 or ZIS2, is a 330 amino acid protein that belongs to the ZRANB2 family.
Localized to the nucleus, ZNF265 functions as a splicing factor that is responsible for alternatively splicing Tra-2 beta (transformer-2 beta) transcripts and is thought to interfere with constitutive 5'-splice selection.
ZNF265 contains two RanBP2-type zinc fingers through which it conveys its RNA-binding activity. Two isoforms, designated ZIS-1 and ZIS-2, are expressed due to alternative splicing events. Upon DNA damage, ZIS-2 may be phosphorylated by ATM or ATR.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Thermo Fisher Scientific 상품 둘러보기
전체보기문의
0개 · 배송·재고 문의는 실시간 상담이 빠릅니다아직 등록된 문의가 없어요.
